Chronomics

Executive Summary

Chronomics is a UK-based diagnostics company leveraging an AI-driven multi-omics platform to deliver personalized health monitoring and precision medicine. By integrating DNA methylation, genomics, proteomics, and metabolomics data, the company provides clinically validated biomarker panels for aging, metabolic health, and early disease detection (including cardiovascular and oncology). Founded in 2020, Chronomics has raised $10M and serves clinicians, consumer health brands, and research organizations, positioning itself at the intersection of multi-omics and digital health. Its platform aims to shift healthcare from reactive to proactive by enabling continuous, multi-layered molecular insights. The company's focus on aging and metabolic health aligns with growing demand for preventive and personalized medicine. With its AI-powered analytics and multi-omics approach, Chronomics differentiates itself from single-omics competitors. The $10M funding likely supports platform development, clinical validations, and commercial expansion. As the company scales, key challenges include navigating regulatory pathways (e.g., UKCA/FDA), demonstrating clinical utility, and driving adoption among healthcare providers. However, the breadth of its biomarker panels and strategic positioning in longevity and early detection offer significant market potential.

Upcoming Catalysts (preview)

• Q2 2026Series B Funding Announcement80% success
• Q3 2026Launch of New Multi-Omics Biomarker Panel for Cardiovascular Risk70% success
• H2 2026Partnership with Major Pharma for Oncology Biomarker Development50% success